KLRS NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Kalaris Therapeutics, Inc. · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 3.51 USD
-5.9% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -46.0% below the Trend Line and sits at 14.1% of its 52-week range. The latest completed week returned -5.9%, after a -26.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 57/100. Near-term considerations: volume confirmation is below normal; earnings are due in 10d.

Setup score 17 out of 100
Latest Close 3.51 USD 31 Jul 2026
1W Return -5.9% latest completed week
4W Return -26.1% short-term follow-through
12W Return -30.9% quarterly tape
Trend Breadth 40.4% 21 of 52 weeks active
Volume Ratio 0.3x vs 13-week average
What is working
  • No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -5.9% Latest completed week; four-week move -26.1%. Indicator stack 22/43 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.07% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 57/100 55 relevant articles in the latest sentiment read. Event risk 10d Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -46.0% below the Trend Line and sits at 14.1% of its 52-week range. The latest completed week returned -5.9%, after a -26.1% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0112-week average 0.08

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -26.1% over four weeks, -30.9% over 12 weeks, and 30.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-5.9%
4W-26.1%
12W-30.9%
26W-60.5%
52W30.5%
Active trend streak0 weeks
Active weeks in one year21
Trend breadth40.4%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.55Latest activity-pressure read.
Pressure change37.4%Four-week change in activity pressure.
Leadership-47.48Latest relative-leadership reading.
RS change-54.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 67% Model confidence 64%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength55/100Blend of value, momentum, and quality. Underlying universe rank 46; rank 1 is best.
Value51/100Relative valuation strength. Underlying universe rank 50; rank 1 is best.
Quality50/100Profitability and accounting quality. Underlying universe rank 51; rank 1 is best.
Momentum52/100Medium-term price momentum. Underlying universe rank 49; rank 1 is best.
Growth52/100Revenue and earnings growth. Underlying universe rank 49; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-87.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-96.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-47.3%
Net share repurchases relative to market value.
Shareholder yield
-47.3%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment57/100

Weighted news tone is neutral across 55 relevant articles.

23 positive · 26 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings10dNext report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-70.5%Distance below the 52-week high.
13-week volatility7.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+15.6%Week of 20 Feb.
Worst week-24.2%Week of 20 Mar.
Latest week-5.9%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains3
Flat weeks0
Modest losses4
Sharp losses12
Recent vol7.8%13-week weekly-return volatility.
Base vol16.1%52-week weekly-return volatility.
Up/down split26/26Count of positive and negative weeks in the 52-week window.
Average skew12.8% / -9.4%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape20/100

Trend, activity pressure, participation, and risk combine to a 20/100 tape read.

 Indicator analysis9/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 40.07%

Next-week expectancy is negative with a 40.07% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors51/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 96; Small Cap Core rank 53 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment57/100

Weighted news tone is neutral across 55 relevant articles.

KLRS|Kalaris Therapeutics Inc|Price:3.380|Chg%:+0.040 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings10d

Next report is scheduled for 12 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20263.51 USD-5.9%6.50 USD15.11 USD-0.55-47.48438.2KOff
24 Jul 20263.73 USD-14.8%6.66 USD15.54 USD-0.46-43.861.3MOff
17 Jul 20264.38 USD-1.4%6.84 USD15.96 USD-0.50-35.0611.2MOff
10 Jul 20264.44 USD-6.5%7.00 USD16.46 USD-0.71-36.65163.1KOff
3 Jul 20264.75 USD10.0%7.15 USD16.95 USD-0.88-30.76336.9KOff
26 Jun 20264.32 USD-8.5%7.18 USD17.39 USD-1.10-36.21356.7KOff
19 Jun 20264.72 USD9.0%7.25 USD17.86 USD-1.15-33.27447.1KOff
12 Jun 20264.33 USD-2.5%7.32 USD18.32 USD-1.21-36.92303.7KOff
5 Jun 20264.44 USD-15.7%7.36 USD19.07 USD-1.04-33.69391.8KOff
29 May 20265.27 USD7.1%7.37 USD19.82 USD-0.98-24.83423.4KOff
22 May 20264.92 USD0.4%7.36 USD20.37 USD-0.94-27.57283.0KOff
15 May 20264.90 USD-3.5%7.36 USD20.91 USD-0.92-26.78643.6KOff
8 May 20265.08 USD-7.0%7.35 USD21.50 USD-0.92-24.31415.1KOff
1 May 20265.46 USD-10.6%7.33 USD22.04 USD-0.83-14.17565.8KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.